Maxim Group set a $4.00 price objective on AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report report published on Wednesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

AEZS has been the subject of several other reports. Zacks Investment Research upgraded AEterna Zentaris from a hold rating to a buy rating and set a $2.50 target price for the company in a report on Tuesday, January 16th. HC Wainwright set a $3.00 target price on AEterna Zentaris and gave the stock a buy rating in a report on Wednesday, November 29th.

Shares of AEterna Zentaris (NASDAQ AEZS) remained flat at $$2.28 during mid-day trading on Wednesday. The company’s stock had a trading volume of 520,623 shares, compared to its average volume of 1,290,000. AEterna Zentaris has a 1 year low of $0.78 and a 1 year high of $3.75. The firm has a market capitalization of $37.13, a PE ratio of -1.26 and a beta of 0.87.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.03). AEterna Zentaris had a negative return on equity of 732.74% and a negative net margin of 2,338.61%. research analysts expect that AEterna Zentaris will post -1.5 EPS for the current year.

An institutional investor recently raised its position in AEterna Zentaris stock. JPMorgan Chase & Co. increased its stake in shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,800 shares of the biopharmaceutical company’s stock after purchasing an additional 46,500 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.35% of AEterna Zentaris worth $120,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.01% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “AEterna Zentaris (AEZS) PT Set at $4.00 by Maxim Group” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/aeterna-zentaris-aezs-pt-set-at-4-00-by-maxim-group/1817096.html.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.